FDA approves new treatment for genetic coagulation disorder

Author(s):

On Dec. 18, the U.S. Food and Drug Administration (FDA) approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in the routine prevention of bleeding in adults and children who have congenital Factor XIII A-subunit deficiency. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here